Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epidermal Growth Factor Receptor Exon 20 Mutant (EGFR Exon 20 Mutant)
- Target
- EGFR Exon 20 Mutant
- Molecular classification
- Receptor Tyrosine Kinase, Transmembrane Receptor
01
Overview
The EGFR Exon 20 mutant represents a clinically significant subset characterized by unique structural changes that drive oncogenesis while conferring substantial therapeutic challenges due to inherent drug resistance properties. Exon 20 mutations occur within the region encoding part of the kinase domain and are frequently associated with acquired resistance to EGFR tyrosine kinase inhibitors. These mutations lead to persistent activation even without ligand stimulation, promoting tumorigenesis through unchecked proliferation.
- Other names
- EGFR Exon 20 insertionEGFR Exon 20 mutationsEGFR Exon 20 SNVs
02
Mechanism of action
Inhibition of EGFR tyrosine kinase activity, disruption of downstream signaling pathways (MAPK, PI3K/AKT, JNK)
03
Biological functions
Cell proliferationCell survivalCell differentiationCell migrationSignal transduction
04
Disease associations
CancerNon-Small Cell Lung Cancer (NSCLC)
05
Safety considerations
Drug resistancePoor response to first/second-generation TKIsMulti-drug resistance in compound mutations
06
Interacting drugs
First-generation EGFR TKIs (e.g., Gefitinib, Erlotinib)
5 more in the full profile.
07
Biomarkers
EGFR Exon 20 insertion mutationsEGFR Exon 20 SNVs (e.g., T790M, S768I, C797S)T790M/L858RT790M/C797X
Beyond the preview
Go deeper on Epidermal Growth Factor Receptor Exon 20 Mutant (EGFR Exon 20 Mutant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epidermal Growth Factor Receptor Exon 20 Mutant (EGFR Exon 20 Mutant).